How will the revision EU General Pharmaceutical Legislation impact Europe’s innovation ecosystem and biotechnology companies?
Van derden07/03/24
Join EuropaBio on 7 March to discuss the impact of revision of the EU’s General Pharmaceutical Legislation (GPL) on Europe’s innovation ecosystem and biotechnology companies.
Following the publication on 24 January 2024 of a new study analysing the expected impact of the GPL on the biotechnology innovation ecosystem, EuropaBio is delighted to invite you to attend its exclusive webinar to discuss the consequences of this landmark legislation for the future of innovation in healthcare in Europe, EU patients and economies within a global race towards health security and competitiveness.
The event will start with a presentation of the study by Charles Rivers Associates and will be followed by a panel discussion featuring leading voices of the European biotechnology ecosystem to discuss the impact of the proposed legislation and its consequences on the development of breakthrough medicines for EU patients.
The webinar will take place on Thursday 7 March at 13.00 CET. If you wish to attend, please register here.
